Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, and CAR-T cell therapy research.
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
A guideline on the molecular ecosystem regulating ferroptosis
The multifunctional protein HMGB1: 50 years of discovery
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee
Clockophagy is a novel selective autophagy process favoring ferroptosis
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc– Activity
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation
The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents
Platelet-derived HMGB1 is a critical mediator of thrombosis
Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation
Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer
HMGB1 in health and disease
Classification of current anticancer immunotherapies
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics
Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Strange attractors: DAMPs and autophagy link tumor cell death and immunity
<scp>PAMP</scp>s and <scp>DAMP</scp>s: signal 0s that spur autophagy and immunity